Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Fears 'Real' Biosimilar Competition Says Russia's Biocad

Executive Summary

Russia's Biocad has lashed out against Roche after being at the receiving end of what it claims are the Swiss multinational's 'scare tactics' against biosimilar competition in Sri Lanka. Biocad says it intends to pursue damages in the Sri Lankan case while Roche, which is standing its ground, has moved the Supreme Court in the island nation.

You may also be interested in...



Indian Court Lifts Curbs On Herceptin Biosimilars; Roche Sticks To Guns

An Indian court has, in a seesaw turn, lifted certain restrictions pertaining to partners Biocon and Mylan’s biosimilar versions of Roche’s Herceptin (trastuzumab). Roche, though, doesn’t seem keen to back off just yet and continues to rake up issues around data requirements for biosimilars.

Indian Court Lifts Curbs On Herceptin Biosimilars; Roche Sticks To Guns

An Indian court has, in a seesaw turn, lifted certain restrictions pertaining to partners Biocon and Mylan’s biosimilar versions of Roche’s Herceptin (trastuzumab). Roche, though, doesn’t seem keen to back off just yet and continues to rake up issues around data requirements for biosimilars.

Russian Blitz, Glenmark Peek Await Indian Biosimilars Arena

Potential new entrants appear to be priming varied approaches to the competitive biosimilars market in India. While a full-fledged Russian challenge may be on the horizon as Biocad readies a basket of products for the Indian market, local firm Glenmark, which has been keen to stay focused on new biological entities (NBEs), now appears to be dipping its toe into the biosimilars segment.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel